Company research
Precipio, Inc.
CIK 1043961Updated Sep 29, 2026
SecurityPRPO · NASDAQ · equity
Name history
TRANSGENOMIC INC · through Jun 30, 2017
PRPO price & chart
Loading TradingView…
NASDAQ:PRPO on TradingView ↗About the company
Precipio is a healthcare biotechnology company focused on cancer diagnostics. Our mission is to address the pervasive problem of cancer misdiagnoses by developing solutions in the form of diagnostic products and services. Our products and services deliver higher accuracy, improved laboratory workflow, and ultimately better patient outcomes, which reduce healthcare expenses. Precipio develops innovative technologies in our laboratory where we design, test, validate, and use these products clinically, improving diagnostic outcomes. Precipio then commercializes these technologies as proprietary products that serve the global laboratory community and further scales Precipio’s reach to eradicate misdiagnosis.
In the news
Precipio to Present at the Planet MicroCap Las Vegas ↗
Recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Regulation FD Disclosure
Items 7.01, 9.01
Submission of Matters to a Vote of Security Holders
Items 5.07
144 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 21,317,000Source | 16,996,000Source | 18,101,000Source | 21,504,000Source |
| Property, Plant and Equipment, NetUSD | 729,000Source | 719,000Source | 739,000Source | 877,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 10,919,000Source | 11,869,000Source | 12,818,000Source | 13,768,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 2,651,000Source | 1,389,000Source | 1,502,000Source | 3,445,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 1,984,000Source | 799,000Source | 1,301,000Source | 1,036,000Source |
| Inventory, NetUSD | 935,000Source | 724,000Source | 384,000Source | 708,000Source |
| Assets, CurrentUSD | 6,039,000Source | 3,451,000Source | 3,682,000Source | 5,710,000Source |
| Operating Lease, Right-of-Use AssetUSD | 2,565,000Source | 395,000Source | 612,000Source | 763,000Source |
| Other Assets, NoncurrentUSD | 67,000Source | 45,000Source | 76,000Source | 129,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 6,756,000Source | 4,902,000Source | 3,672,000Source | 5,137,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 18,000Source | 15,000Source | 14,000Source | 228,000Source |
| Additional Paid in CapitalUSD | 117,346,000Source | 114,519,000Source | 112,565,000Source | 108,371,000Source |
| Retained Earnings (Accumulated Deficit)USD | -102,803,000Source | -102,440,000Source | -98,150,000Source | -92,297,000Source |
| Stockholders' Equity Attributable to ParentUSD | — | — | 14,429,000Source | 16,302,000Source |
| Liabilities and EquityUSD | 21,317,000Source | 16,996,000Source | 18,101,000Source | 21,504,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 3,752,000Source | 4,271,000Source | 3,141,000Source | 4,361,000Source |
| Operating Lease, Liability, CurrentUSD | 410,000Source | 201,000Source | 218,000Source | 199,000Source |
| Accounts Payable, CurrentUSD | 1,131,000Source | 618,000Source | 622,000Source | 2,042,000Source |
| Operating Lease, Liability, NoncurrentUSD | 2,206,000Source | 206,000Source | 407,000Source | 574,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | — | — | — | 65,000Source |
| Additional Financial Items | ||||
| Accounts Receivable, after Allowance for Credit LossUSD | 1,984,000Source | 799,000Source | 1,301,000Source | 1,036,000Source |
| Accrued Liabilities, CurrentUSD | 1,690,000Source | 2,799,000Source | 1,824,000Source | 1,584,000Source |
| Deferred Tax Liabilities, NetUSD | 0Source | 0Source | 0Source | 0Source |
| Long-term Debt, Excluding Current Maturities | — | — | — | — |
| Long-term Debt, Current MaturitiesUSD | 30,000Source | 297,000Source | 235,000Source | 255,000Source |
| Long-term Debt, Excluding Current MaturitiesUSD | 47,000Source | 77,000Source | 106,000Source | 134,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -363,000Source | -4,290,000Source | -5,853,000Source | -12,178,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 1,245,000Source | 1,199,000Source | 1,225,000Source | 1,219,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 1,209,000Source | 1,491,000Source | 1,558,000Source | 3,801,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 1,362,000Source | -438,000Source | 483,000Source | 745,000Source |
| Increase (Decrease) in InventoriesUSD | 211,000Source | 340,000Source | -324,000Source | 144,000Source |
| Increase (Decrease) in Accounts PayableUSD | 513,000Source | -10,000Source | -169,000Source | 165,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | 685,000Source | 439,000Source | -3,559,000Source | -7,721,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -326,000Source | -223,000Source | -126,000Source | -277,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 326,000Source | 223,000Source | 126,000Source | 277,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 903,000Source | -329,000Source | 1,742,000Source | -225,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 1,262,000Source | -113,000Source | -1,943,000Source | -8,223,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 2,651,000Source | 1,389,000Source | 1,502,000Source | 3,445,000Source |
| Supplemental disclosure of cash flow information: | ||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | 100,000Source | 85,000Source | 42,000Source | 45,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 1,200,000Source | 1,500,000Source | 1,600,000Source | 3,800,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | 3,000Source | 3,000Source | 3,000Source | 4,000Source |
| Amortization of Intangible AssetsUSD | 1,000,000Source | 1,000,000Source | 1,000,000Source | 1,000,000Source |
| DepreciationUSD | 300,000Source | 300,000Source | 300,000Source | 300,000Source |
| Gain (Loss) on Disposition of AssetsUSD | -20,000Source | — | — | — |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | 25,000Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | 0Source | 0Source | 0Source | 0Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | -363,000Source | — | — | — |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | 25,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -5,853,000Source | -12,203,000Source |
| Operating ExpensesUSD | 11,908,000Source | 11,775,000Source | 13,638,000Source | 15,307,000Source |
| Other Nonoperating Income (Expense)USD | 839,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | — | 78,000Source | 2,245,000Source | 129,000Source |
| Proceeds from Issuance of Long-term DebtUSD | — | 250,000Source | — | — |
| Proceeds from Stock Options ExercisedUSD | 119,000Source | — | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 53,492,000Source | 41,784,000Source | 29,509,000Source | 20,290,000Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 24,246,000Source | 18,576,000Source | 15,415,000Source | 9,820,000Source |
| Cost of RevenueUSD | 13,343,000Source | 10,973,000Source | 9,179,000Source | 6,902,000Source |
| Operating Income (Loss)USD | -1,202,000Source | -4,216,000Source | -7,620,000Source | -12,797,000Source |
| Other Nonoperating Income (Expense)USD | 839,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -363,000Source | -4,290,000Source | -5,853,000Source | -12,178,000Source |
| Income Tax Expense (Benefit)USD | 0Source | 0Source | 0Source | 0Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | 25,000Source |
| Net Income (Loss) Attributable to ParentUSD | -363,000Source | — | — | — |
| Earnings Per Share, BasicUSD per share | -0.23Source | -2.93Source | -4.51Source | -0.54Source |
| Earnings Per Share, DilutedUSD per share | -0.23Source | -2.93Source | -4.51Source | -0.54Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,605,080Source | 1,465,518Source | 1,297,851Source | 22,751,460Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,605,080Source | 1,465,518Source | 1,297,851Source | 22,751,460Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 1,000,000Source | 1,000,000Source | 1,000,000Source | 1,000,000Source |
| Gain (Loss) Related to Litigation SettlementUSD | — | — | — | 25,000Source |
| Gross ProfitUSD | 10,706,000Source | 7,559,000Source | 6,018,000Source | 2,510,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -363,000Source | — | — | — |
| Interest Income (Expense), Nonoperating, NetUSD | -73,000Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -5,853,000Source | -12,203,000Source |
| Operating ExpensesUSD | 11,908,000Source | 11,775,000Source | 13,638,000Source | 15,307,000Source |
| Other IncomeUSD | — | — | 65,000Source | — |
| Research and Development ExpenseUSD | 1,600,000Source | 1,300,000Source | 1,700,000Source | 1,700,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | 53,492,000Source | 41,784,000Source | 29,509,000Source | 20,290,000Source |
Filing attachments
tm2623274d1_ex99-1.htm · 8-K · 2026-08-14
EX-99.1 2 tm2623274d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Precipio Announces Q2-2026 Financial Results Revenue reaches quarterly record as Precipio returns to positive Adjusted EBITDA and strengthens cash position NEW HAVEN, CT, Globenewswire - (Aug 14, 2026) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces financial results for the second quarter that ended June 30, 2026. Below are some of the key financial performance metrics for the Company. For addition…
Read attachment ↗tm2621816d1_ex99-1.htm · 8-K · 2026-07-31
EX-99.1 2 tm2621816d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Precipio Announces Q2-2026 Shareholder Update Call Conference Call will be held on August 17th, 2026, at 5:00 PM EST NEW HAVEN, CT, (July 31st, 2026) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2026 shareholder update call on August 17 th, 2026, at 5:00 PM ET. The call will include remarks on the company’s current core businesses, as well as a moderated live Q&A session at the end o…
Read attachment ↗tm2613783d1_ex99-1.htm · 8-K · 2026-05-06
EX-99.1 2 tm2613783d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Precipio Announces Q1-2026 Shareholder Update Call Conference Call will be held on May 18th, 2026, at 5:00 PM EST NEW HAVEN, CT, (May 6th, 2026) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q1-2026 shareholder update call on May 18 th, 2026, at 5:00 PM ET. The call will include remarks on the company’s current core businesses, as well as a moderated live Q&A session at the end of the Co…
Read attachment ↗tm267591d1_ex99-1.htm · 8-K · 2026-02-27
EX-99.1 2 tm267591d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Precipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-Year In Q4-2025 the Company generated ~$400K in Operating Cash Flow, and Adjusted EBITDA of close to $1M NEW HAVEN, CT, Globenewswire - (February 25, 2026) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces some preliminary (unaudited) financials for Q4-2025 and for its fiscal year 2025. Below are some of the key financial perf…
Read attachment ↗tm2530457d1_ex99-1.htm · 8-K · 2025-11-06
EX-99.1 2 tm2530457d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Precipio Announces Q3-2025 Shareholder Update Call Conference Call to be held on November 17th, 2025 at 5:00 PM EST NEW HAVEN, CT, (November 4th, 2025) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2025 corporate update call on November 17 th, 2025 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses. The conference call may be accessed by call…
Read attachment ↗tm2525140d1_ex99-1.htm · 8-K · 2025-09-03
EX-99.1 2 tm2525140d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Precipio Terminates Its ATM Management Decision Further Reinforces Commitment to Responsible Capital Management NEW HAVEN, CT, (September 3rd, 2025) - Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), has terminated its ATM (At-The-Market) instrument with investment bank Alliance Global Partners (AGP). “Our Company is in a much stronger position today than it was when we entered into this structure. With our eli…
Read attachment ↗